Mohit Bansal
Stock Analyst at Wells Fargo
(4.21)
# 466
Out of 5,111 analysts
185
Total ratings
67.29%
Success rate
9.3%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,200 | $1,056.50 | +13.58% | 18 | Dec 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $53 → $55 | $53.94 | +1.97% | 10 | Dec 10, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $460 → $515 | $455.16 | +13.15% | 12 | Dec 10, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $700 → $745 | $743.00 | +0.27% | 21 | Dec 10, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $119.84 | +25.17% | 13 | Dec 10, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $155 → $190 | $170.89 | +11.18% | 15 | Dec 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $325 | $324.32 | +0.21% | 12 | Dec 10, 2025 | |
| MRK Merck & Co. | Upgrades: Overweight | $90 → $125 | $97.51 | +28.19% | 12 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $170 → $235 | $169.02 | +39.04% | 3 | Nov 18, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $1 → $3 | $3.53 | -15.01% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $36.39 | +51.14% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $70 | $52.11 | +34.33% | 6 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $224.44 | +15.84% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $35.25 | -0.71% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4 | $2.38 | +68.07% | 1 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $93.49 | +60.44% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $43.68 | +7.61% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $65 | $63.08 | +3.04% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $17.26 | +73.81% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $49.30 | +41.99% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.61 | +17.14% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $153.40 | +10.82% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $22.36 | +8,285.51% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $3.04 | +1,084.21% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $11.16 | +70.33% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.15 | +5,117.39% | 4 | Dec 3, 2019 |
Eli Lilly and Company
Dec 10, 2025
Maintains: Overweight
Price Target: $1,100 → $1,200
Current: $1,056.50
Upside: +13.58%
Bristol-Myers Squibb Company
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $53 → $55
Current: $53.94
Upside: +1.97%
Vertex Pharmaceuticals
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $455.16
Upside: +13.15%
Regeneron Pharmaceuticals
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $700 → $745
Current: $743.00
Upside: +0.27%
Gilead Sciences
Dec 10, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $119.84
Upside: +25.17%
Biogen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $155 → $190
Current: $170.89
Upside: +11.18%
Amgen
Dec 10, 2025
Maintains: Equal-Weight
Price Target: $300 → $325
Current: $324.32
Upside: +0.21%
Merck & Co.
Nov 24, 2025
Upgrades: Overweight
Price Target: $90 → $125
Current: $97.51
Upside: +28.19%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $170 → $235
Current: $169.02
Upside: +39.04%
Ironwood Pharmaceuticals
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $1 → $3
Current: $3.53
Upside: -15.01%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $36.39
Upside: +51.14%
Oct 28, 2025
Maintains: Overweight
Price Target: $90 → $70
Current: $52.11
Upside: +34.33%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $224.44
Upside: +15.84%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $35.25
Upside: -0.71%
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $2.38
Upside: +68.07%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $93.49
Upside: +60.44%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $43.68
Upside: +7.61%
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $63.08
Upside: +3.04%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $17.26
Upside: +73.81%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $49.30
Upside: +41.99%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.61
Upside: +17.14%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $153.40
Upside: +10.82%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $22.36
Upside: +8,285.51%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $3.04
Upside: +1,084.21%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $11.16
Upside: +70.33%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.15
Upside: +5,117.39%